pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search

calendar

3,701 catalysts · 4,728 grant · 3,364 device 510k · 3,124 8k filing · 2,853 approval · 2,000 device pma · 2,000 device recall

★ save view↓export CSV
next 91 dayslessmore
MonWedFri
2026-08-10: 0 catalysts2026-08-11: 95 catalysts2026-08-12: 19 catalysts2026-08-13: 19 catalysts2026-08-14: 4 catalysts2026-08-15: 0 catalysts2026-08-16: 0 catalysts2026-08-17: 1 catalyst2026-08-18: 2 catalysts2026-08-19: 2 catalysts2026-08-20: 0 catalysts2026-08-21: 0 catalysts2026-08-22: 0 catalysts2026-08-23: 0 catalysts2026-08-24: 0 catalysts2026-08-25: 0 catalysts2026-08-26: 1 catalyst2026-08-27: 1 catalyst2026-08-28: 0 catalysts2026-08-29: 0 catalysts2026-08-30: 0 catalysts2026-08-31: 0 catalysts2026-09-01: 1 catalyst2026-09-02: 0 catalysts2026-09-03: 1 catalyst2026-09-04: 0 catalysts2026-09-05: 0 catalysts2026-09-06: 0 catalysts2026-09-07: 0 catalysts2026-09-08: 0 catalysts2026-09-09: 0 catalysts2026-09-10: 0 catalysts2026-09-11: 0 catalysts2026-09-12: 0 catalysts2026-09-13: 0 catalysts2026-09-14: 0 catalysts2026-09-15: 0 catalysts2026-09-16: 0 catalysts2026-09-17: 0 catalysts2026-09-18: 0 catalysts2026-09-19: 0 catalysts2026-09-20: 0 catalysts2026-09-21: 0 catalysts2026-09-22: 0 catalysts2026-09-23: 2 catalysts2026-09-24: 0 catalysts2026-09-25: 0 catalysts2026-09-26: 0 catalysts2026-09-27: 0 catalysts2026-09-28: 0 catalysts2026-09-29: 0 catalysts2026-09-30: 0 catalysts2026-10-01: 0 catalysts2026-10-02: 0 catalysts2026-10-03: 0 catalysts2026-10-04: 0 catalysts2026-10-05: 0 catalysts2026-10-06: 0 catalysts2026-10-07: 0 catalysts2026-10-08: 2 catalysts2026-10-09: 0 catalysts2026-10-10: 0 catalysts2026-10-11: 0 catalysts2026-10-12: 0 catalysts2026-10-13: 1 catalyst2026-10-14: 1 catalyst2026-10-15: 0 catalysts2026-10-16: 0 catalysts2026-10-17: 0 catalysts2026-10-18: 0 catalysts2026-10-19: 1 catalyst2026-10-20: 2 catalysts2026-10-21: 2 catalysts2026-10-22: 2 catalysts2026-10-23: 1 catalyst2026-10-24: 0 catalysts2026-10-25: 0 catalysts2026-10-26: 1 catalyst2026-10-27: 8 catalysts2026-10-28: 12 catalysts2026-10-29: 21 catalysts2026-10-30: 4 catalysts2026-10-31: 0 catalysts2026-11-01: 0 catalysts2026-11-02: 9 catalysts2026-11-03: 18 catalysts2026-11-04: 22 catalysts2026-11-05: 37 catalysts2026-11-06: 2 catalysts2026-11-07: 0 catalysts2026-11-08: 0 catalysts
view
agendamonth
sort
soonestlatesttypesponsoralpha
type: recall×type: approval×from 2025-04-02×clear all
type
  • grant4,728
  • device 510k3,364
  • 8k filing3,124
  • approval2,853
  • device pma2,000
  • device recall2,000
device adverse event
1,000
  • recall848
  • earnings583
  • phase 2 completion172
  • therapy area

    no tagged catalysts yet

    Week of Mar 31, 2025

    24
    ›Apr 2, 2025approval497d agoVANRAFIA (ATRASENTAN HYDROCHLORIDE) — FDA approvalatrasentan hydrochloride

    Sponsor: NOVARTIS. Form: TABLET. Route: ORAL

    full page →atrasentan hydrochloride →fda approvals ↗
    ›Apr 2, 2025approval497d agoLIRAGLUTIDE — FDA approvalNovo Nordisk Inc

    Sponsor: NANJING KING FRIEND. Form: SOLUTION. Route: SUBCUTANEOUS

    full page →fda approvals ↗
    ›Apr 2, 2025approval497d agoLIDOCAINE HYDROCHLORIDE — FDA approvalInternational Medication Systems Ltd

    Sponsor: ANTHEA PHARMA. Form: INJECTABLE. Route: INJECTION

    full page →fda approvals ↗
    ›Apr 2, 2025recall497d agoA-S Medication Solutions LLC recall (Cls II)A-S Medication Solutions LLC

    METFORMIN HYDROCHLORIDE EXTENDED- RELEASE 500MG, 180 TABLETS, Packaged BY: A-S Medication Solutions, Libertyville, IL 60048 NDC 50090-1494-3. — Reason: Presence of Foreign Tablets/Capsules. — Status: Ongoing

    full page →fda recalls ↗
    ›Apr 2, 2025recall497d agoQuVa Pharma, Inc. recall (Cls II)IGC Pharma, Inc.

    fentaNYL Citrate PF 200 mcg/100 mL (2 mcg/ml) /0.125% Bupivacaine HCl 125 mg/100 mL (1.25 mg/mL), 100 ml in NS Yellow CADD FSFF, Injection for Epidural Use (Not intended For IV Use), Compounded, For Institutional or Office Use Only, QuVa Pharma, 1075 West Park One Drive, Suite 100, Sugar Land, Tx 77478. NDC: 70092-1255-75 — Reason: Lack of Assurance of Sterility — Status: Ongoing

    full page →fda recalls ↗
    ›Apr 2, 2025recall497d agoConsumer Product Partners, LLC recall (Cls II)Kortuc Japan LLC

    [CORRECT FRONT PANEL] Hydrogen Peroxide Topical Solution, USP, 32 FL OZ (1 QT) 946 mL per bottle, NDC 0869-0871-45; [INCORRECT BACK LABEL] Isopropyl alcohol 91%, Dist. by: Amazon.com Services, LLC, Seattle, WA 98109. — Reason: Labeling; Label Mixup; some bottles have an incorrect back label indicating 91% Isopropyl Alcohol — Status: Ongoing

    full page →fda recalls ↗
    ›Apr 2, 2025recall497d agoExela Pharma Sciences LLC recall (Cls II)Exela Pharma Sciences LLC

    8.4% Sodium Bicarbonate Injection, USP, 50 mEq/50 mL (1 mEq/mL), 25 x 50 mL Single Dose Vials per carton, For Intravenous Use Only, Rx Only, Manufactured by: Exela Pharma Sciences, LLC, Lenoir, NC 28645. NDC Inner Vial: 51754-5001-1; NDC Carton: 51754-5001-4 — Reason: Lack of Assurance of Sterility — Status: Ongoing

    full page →fda recalls ↗
    ›Apr 2, 2025recall497d agoAscent Consumer Products Inc. recall (Cls I)Reynolds Consumer Products Inc.

    SinuCleanse Soft Tip Squeeze Bottle Nasal Wash System (sodium bicarbonate USP 700 mg and sodium chloride USP 2300 mg), 30-count All Natural USP Grade Saline Packets and 1 Soft tip Squeeze Bottle, Net WT 0.1OZ (3g) each, Distributed by Ascent Consumer Products Inc., Melville, NY 11747, UPC 6 46011 00104 1 — Reason: Microbial Contamination of Non-Sterile Products: Bacterial contamination with Staphylococcus aureus — Status: Ongoing

    full page →fda recalls ↗
    ›Apr 2, 2025recall497d agoAscent Consumer Products Inc. recall (Cls I)Reynolds Consumer Products Inc.

    SinuCleanse Soft Tip NETI POT Nasal Wash System (sodium bicarbonate USP 700 mg and sodium chloride USP 2300 mg), 30-count All Natural USP Grade Saline Packets and 1 kettle style Neti Pot, Net WT 0.1OZ (3g) each, Distributed by Ascent Consumer Products Inc., Melville, NY 11747, UPC 6 46011 00102 7 — Reason: Microbial Contamination of Non-Sterile Products: Bacterial contamination with Staphylococcus aureus — Status: Ongoing

    full page →fda recalls ↗
    ›Apr 2, 2025recall497d agoQuVa Pharma, Inc. recall (Cls II)IGC Pharma, Inc.

    fentaNYL Citrate PF 200 mcg/100 mL (2 mcg/ml) /0.1% Bupivacaine HCl 100 mg/100 mL (1 mg/mL), 100 ml in NS Yellow CADD FSFF, Injection for Epidural Use (Not intended For IV Use), Compounded, For Institutional or Office Use Only, QuVa Pharma, 1075 West Park One Drive, Suite 100, Sugar Land, Tx 77478. NDC: 70092-1255-75 — Reason: Lack of Assurance of Sterility — Status: Ongoing

    full page →fda recalls ↗
    ›Apr 2, 2025recall497d agoAscent Consumer Products Inc. recall (Cls I)Reynolds Consumer Products Inc.

    SinuCleanse Premixed SALINE PACKETS (sodium bicarbonate USP 700 mg and sodium chloride USP 2300 mg) for Nasal Wash System, 60-count All Natural USP Grade Saline Packets, Net WT 0.1OZ (3g) each, Distributed by Ascent Consumer Products Inc., Melville, NY 11747, UPC 6 46011 00103 4 — Reason: Microbial Contamination of Non-Sterile Products: Bacterial contamination with Staphylococcus aureus — Status: Ongoing

    full page →fda recalls ↗
    ›Apr 2, 2025recall497d agoStrides Pharma, Inc. recall (Cls II)Strides Pharma Inc

    Testosterone Gel 1%, 5 grams, 30 Unit-dose Packets in a carton, Rx only, Distributed by: Strides Pharma Inc., East Brunswick, NJ, NDC 64380-152-02 — Reason: Presence of foreign substance: Presence of Benzene. — Status: Ongoing

    full page →fda recalls ↗
    ›Apr 2, 2025recall497d agoJohnson, S C and Son, Inc recall (Cls II)

    babyganics, Sheer Blend, SPF 50 Mineral Sunscreen Fragrance Free (zinc oxide 20%), a) 1.7 FL OZ (50 mL) bottle, UPC 810035921658, b) 8 FL OZ (236 mL) bottle, UPC 810035921382, Dist. by KAS Direct, LLC, 1525 Howe St., Racine, WI 53403, Made in Canada. — Reason: Failed stability specifications: during routine stability monitoring quality concerns were identified. Physical separation for ingredients was observed. — Status: Ongoing

    full page →fda recalls ↗
    ›Apr 2, 2025recall497d agoQuVa Pharma, Inc. recall (Cls II)IGC Pharma, Inc.

    fentaNYL Citrate PF 200 mcg/100 mL (2 mcg/ml) /0.2% ROPivacaine HCl 200 mg/100 mL (2 mg/mL), 100 ml in NS Yellow CADD FSFF, Injection for Epidural Use (Not intended For IV Use), Compounded, For Institutional or Office Use Only, QuVa Pharma, 1075 West Park One Drive, Suite 100, Sugar Land, Tx 77478. NDC: 70092-1259-75 — Reason: Lack of Assurance of Sterility — Status: Ongoing

    full page →fda recalls ↗
    ›Apr 2, 2025recall497d agoStrides Pharma, Inc. recall (Cls II)Strides Pharma Inc

    Testosterone Gel 1%, 2.5 grams, 30 Unit-dose packets in a carton, Rx only, Distributed by: Strides Pharma Inc., East Brunswick, NJ, NDC 64380-151-02 — Reason: Presence of foreign substance: Presence of Benzene. — Status: Ongoing

    full page →fda recalls ↗
    ›Apr 3, 2025approval496d agoHYDROCODONE BITARTRATE AND ACETAMINOPHEN (ACETAMINOPHEN) — FDA approvalacetaminophen ER

    Sponsor: SPECGX LLC. Form: TABLET. Route: ORAL

    full page →acetaminophen ER →fda approvals ↗
    ›Apr 3, 2025approval496d agoHYDROCODONE BITARTRATE AND ACETAMINOPHEN (ACETAMINOPHEN) — FDA approvalacetaminophen ER

    Sponsor: WES PHARMA INC. Form: TABLET. Route: ORAL

    full page →acetaminophen ER →fda approvals ↗
    ›Apr 3, 2025approval496d agoUPLIZNA (INEBILIZUMAB-CDON) — FDA approvalHorizon Therapeutics USA Inc

    Sponsor: VIELA BIO. Form: INJECTABLE. Route: INJECTION

    full page →fda approvals ↗
    ›Apr 4, 2025approval495d agoSIVEXTRO (TEDIZOLID PHOSPHATE) — FDA approvaltedizolid phosphate

    Sponsor: CUBIST PHARMS LLC. Form: TABLET. Route: ORAL

    full page →tedizolid phosphate →fda approvals ↗
    ›Apr 4, 2025approval495d agoSIVEXTRO (TEDIZOLID PHOSPHATE) — FDA approvaltedizolid phosphate

    Sponsor: CUBIST PHARMS LLC. Form: POWDER. Route: INTRAVENOUS

    full page →tedizolid phosphate →fda approvals ↗
    ›Apr 4, 2025approval495d agoAMBRISENTAN — FDA approvalAMBRISENTAN

    Sponsor: WATSON LABS INC. Form: TABLET. Route: ORAL

    full page →AMBRISENTAN →fda approvals ↗
    ›Apr 4, 2025approval495d agoAMBRISENTAN — FDA approvalAMBRISENTAN

    Sponsor: SIGMAPHARM LABS LLC. Form: TABLET. Route: ORAL

    full page →AMBRISENTAN →fda approvals ↗
    ›Apr 4, 2025approval495d agoAMBRISENTAN — FDA approvalSigmapharm Laboratories LLC

    Sponsor: SUN PHARM. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Apr 4, 2025approval495d agoAMBRISENTAN — FDA approvalAMBRISENTAN

    Sponsor: APOTEX. Form: TABLET. Route: ORAL

    full page →AMBRISENTAN →fda approvals ↗

    Week of Apr 7, 2025

    23
    ›Apr 7, 2025approval492d agoMEKINIST (TRAMETINIB) — FDA approvalSpexotras

    Sponsor: NOVARTIS. Form: SOLUTION. Route: ORAL

    full page →Spexotras →fda approvals ↗
    ›Apr 7, 2025approval

    Week of Apr 14, 2025

    3
    ›Apr 14, 2025approval485d agoOTULFI (USTEKINUMAB-AAUZ) — FDA approvalOTULFI

    Sponsor: FRESENIUS KABI USA. Form: INJECTABLE. Route: INJECTION

    full page →OTULFI →fda approvals ↗
    ›Apr 14, 2025approval
    ← prev
    page 1 of 75
    next →
    492d ago
    TAFINLAR (DABRAFENIB MESYLATE) — FDA approvaldabrafenib mesylate ODT

    Sponsor: NOVARTIS. Form: CAPSULE. Route: ORAL

    full page →dabrafenib mesylate ODT →fda approvals ↗
    ›Apr 7, 2025approval492d agoMEKINIST (TRAMETINIB DIMETHYL SULFOXIDE) — FDA approvalSpexotras

    Sponsor: NOVARTIS. Form: TABLET. Route: ORAL

    full page →Spexotras →fda approvals ↗
    ›Apr 7, 2025approval492d agoTAFINLAR (DABRAFENIB MESYLATE) — FDA approvaldabrafenib mesylate ODT

    Sponsor: NOVARTIS. Form: CAPSULE. Route: ORAL

    full page →dabrafenib mesylate ODT →fda approvals ↗
    ›Apr 7, 2025approval492d agoSIMLANDI (ADALIMUMAB-RYVK) — FDA approvalAlvotech

    Sponsor: ALVOTECH USA INC. Form: INJECTABLE. Route: INJECTION

    full page →fda approvals ↗
    ›Apr 7, 2025approval492d agoSIMLANDI (ADALIMUMAB-RYVK) — FDA approvalAlvotech

    Sponsor: ALVOTECH USA INC. Form: INJECTABLE. Route: INJECTION

    full page →fda approvals ↗
    ›Apr 7, 2025approval492d agoAMJEVITA (ADALIMUMAB-ATTO) — FDA approvalAMJEVITA

    Sponsor: AMGEN INC. Form: INJECTABLE. Route: INJECTION

    full page →AMJEVITA →fda approvals ↗
    ›Apr 7, 2025approval492d agoYUFLYMA (ADALIMUMAB-AATY) — FDA approvalYUFLYMA

    Sponsor: CELLTRION. Form: INJECTABLE. Route: INJECTION

    full page →YUFLYMA →fda approvals ↗
    ›Apr 8, 2025approval491d agoOPDIVO (NIVOLUMAB) — FDA approvalnivolumab

    Sponsor: BRISTOL MYERS SQUIBB. Form: INJECTABLE. Route: INJECTION

    full page →nivolumab →fda approvals ↗
    ›Apr 8, 2025approval491d agoFINTEPLA (FENFLURAMINE HYDROCHLORIDE) — FDA approvalfenfluramine hydrochloride

    Sponsor: UCB INC. Form: SOLUTION. Route: ORAL

    full page →fenfluramine hydrochloride →fda approvals ↗
    ›Apr 9, 2025recall490d agoBIOCON PHARMA INC recall (Cls II)Pharma-Bio Serv, Inc.

    Atorvastatin Calcium Tablets USP 40 mg, 1000-count bottle, Rx Only, Manufactured for: Biocon Pharma Inc., Iselin, NJ 08830-3009 USA, Manufactured by: Recipharm Pharmaservices PVT, Ltd Bengaluru, INDIA -562-123, NDC 70377-079-13 — Reason: Failed dissolution specifications: lower than specifications — Status: Ongoing

    full page →fda recalls ↗
    ›Apr 9, 2025recall490d agoThe Harvard Drug Group LLC dba Major Pharmaceuticals and Rugby Laboratories recall (Cls III)Teva Pharmaceuticals USA Inc

    Tolterodine Tartrate Extended-Release Capsules, 2 mg, 30 Capsules (3 x 10) Unit Dose carton, Rx only, Packaged and Distributed by: Major Pharmaceuticals, Indianapolis, IN 46268 USA, NDC 0904-6592-04. — Reason: Failed Dissolution Specifications: Out of specification results obtained during routine stability testing for dissolution. — Status: Terminated

    full page →fda recalls ↗
    ›Apr 9, 2025recall490d agoImprimis NJOF, LLC recall (Cls III)Sawai Man Singh Medical College

    Tropicamide - Proparacaine - Phenylephrine - Ketorolac Sterile Ophthalmic Solution, 1% 0.5% 2.5% 0.5%, 5 mL fill in 15 mL bottle, Imprimis NJOF, LLC, Route 46 West, Unit 6B, Ledgewood, NJ, 07852, NDC: 71384-733-05. — Reason: Sub-Potent Drug: The stability batch showed a subpotent result, which does not meet the product specifications of 90.0-110.0% of the label claim. — Status: Ongoing

    full page →fda recalls ↗
    ›Apr 9, 2025recall490d agoAmerisource Health Services LLC recall (Cls II)Greenstone LLC

    Voriconazole Tablets, 50 mg, packaged in cartons of 3 blister cards with 10 individual blistered doses (30 Unit Dose per carton), Rx only, Distributed by: American Health Packaging, Columbus, Ohio 43217, Carton NDC 60687-294-21, Unit Dose NDC 60687-294-11. — Reason: cGMP Deviations: Received notification from their supplier requesting they perform a recall due to the fact they repackaged the product. — Status: Terminated

    full page →fda recalls ↗
    ›Apr 9, 2025recall490d agoBreckenridge Pharmaceutical, Inc. recall (Cls II)Breckenridge Pharmaceutical Inc

    Duloxetine Delayed-Release Capsules, USP, 30 mg, Rx Only, 1,000 Capsules per bottle, Manufactured by: Towa Pharmaceutical Europe, S.L., Martorelles, (Barcelona), Spain, Distributed by: Breckenridge Pharmaceutical, Inc., Berkley Heights, NJ 07922, NDC 51991-747-10. — Reason: CGMP Deviations: presence of Nitrosamine Drug Substance Related Impurity (NDSRI), N-nitroso-duloxetine, above the recommended interim limit. — Status: Ongoing

    full page →fda recalls ↗
    ›Apr 9, 2025recall490d agoGlenmark Pharmaceuticals Inc., USA recall (Cls II)LB PHARMACEUTICALS INC

    chlorproMAZINE Hydrochloride Tablets, USP 100 mg, Rx Only, 100 Tablets per bottle, Manufactured for: Glenmark Pharmaceuticals Inc., USA, Mahwah, NJ 07430, Product of India, NDC 68462-864-01 — Reason: CGMP deviations: presence of N-Nitroso-Desmethyl Chlorpromazine impurity above the recommended interim limit. — Status: Ongoing

    full page →fda recalls ↗
    ›Apr 10, 2025approval489d agoVYVGART HYTRULO (EFGARTIGIMOD ALFA AND HYALURONIDASE-QVFC) — FDA approvalARGENX SE

    Sponsor: ARGENX BV. Form: INJECTABLE. Route: INJECTION

    full page →fda approvals ↗
    ›Apr 10, 2025approval489d agoTEPADINA AND SODIUM CHLORIDE (THIOTEPA) — FDA approvalRevalesio Corp

    Sponsor: ADIENNE SA. Form: POWDER. Route: INTRAVENOUS

    full page →fda approvals ↗
    ›Apr 10, 2025approval489d agoLOPRESSOR (METOPROLOL TARTRATE) — FDA approvalmetoprolol tartrate

    Sponsor: RUBICON RESEARCH. Form: SOLUTION. Route: ORAL

    full page →metoprolol tartrate →fda approvals ↗
    ›Apr 11, 2025approval488d agoOPDIVO (NIVOLUMAB) — FDA approvalnivolumab

    Sponsor: BRISTOL MYERS SQUIBB. Form: INJECTABLE. Route: INJECTION

    full page →nivolumab →fda approvals ↗
    ›Apr 11, 2025approval488d agoSUBLOCADE (BUPRENORPHINE) — FDA approvalbuprenorphine LA

    Sponsor: INDIVIOR. Form: SOLUTION, EXTENDED RELEASE. Route: SUBCUTANEOUS

    full page →buprenorphine LA →fda approvals ↗
    ›Apr 11, 2025approval488d agoMORPHINE SULFATE — FDA approvalKapanol

    Sponsor: ACTAVIS ELIZABETH. Form: CAPSULE, EXTENDED RELEASE. Route: ORAL

    full page →Kapanol →fda approvals ↗
    ›Apr 11, 2025approval488d agoCABENUVA KIT (CABOTEGRAVIR) — FDA approvalViiV Healthcare Company

    Sponsor: VIIV HLTHCARE. Form: SUSPENSION, EXTENDED RELEASE. Route: INTRAMUSCULAR

    full page →fda approvals ↗
    485d ago
    ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE (ACETAMINOPHEN) — FDA approvalIGC Pharma, Inc.

    Sponsor: PHARMOBEDIENT. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Apr 15, 2025approval484d agoISTURISA (OSILODROSTAT PHOSPHATE) — FDA approvalosilodrostat phosphate

    Sponsor: RECORDATI RARE. Form: TABLET. Route: ORAL

    full page →osilodrostat phosphate →fda approvals ↗
    $NVS155.21-1.01%
    $IGC0.2670+0.41%
    $IGC0.2670+0.41%
    $REYN25.95-0.69%
    $IGC0.2670+0.41%
    $REYN25.95-0.69%
    $IGC0.2670+0.41%
    $REYN25.95-0.69%
    $NVS155.21-1.01%
    $NVS155.21-1.01%
    $NVS155.21-1.01%
    $ALVO3.8200+1.33%
    $ALVO3.8200+1.33%
    $NVS155.21-1.01%
    $AMGN414.03-0.76%
    $BMY63.75-1.68%
    $PBSV
    $ARGX863.55-0.30%
    $LBRX45.52-0.72%
    $BMY63.75-1.68%
    $INDV39.20+1.90%
    $IGC0.2670+0.41%